Mylan, Biocon target Sanofi with deeply discounted Lantus copycat 03-Sep-2020 By Nick Taylor Mylan and Biocon price copy of Sanofi’s Lantus at 65% discount, setting up a fight for the blockbuster diabetes opportunity.
Five big pharma deals in Humira market could save UK £300m 30-Nov-2018 By Flora Southey At least 80% of patients currently taking AbbVie’s blockbuster drug could be switched to “the best value biological medicine” within 12 months, according to the UK National Health Service.
Coherus receives US FDA approval for Neulasta biosimilar, pricing 33% lower 09-Nov-2018 By Ben Hargreaves The company will launch Udenyca onto the US market on January 3, 2019, to compete with Amgen’s originator product and Mylan’s rival biosimilar.
EU Humira biosimilar discounts at ‘higher end’ of scale, says AbbVie 06-Nov-2018 By Ben Hargreaves In Europe, biosimilar rivals have undercut Humira’s list price from 10% to 80%, says AbbVie CEO.
CHMP nod for Ogivri: Biocon and Mylan expect EC call by end of year 23-Oct-2018 By Flora Southey Roche remains confident new medicines will compensate for biosimilar impact, as another version of blockbuster Herceptin nears EU approval.